Complementary Approaches to Improving Glucose Control--Insulin and Incretins: Patient Case Studies in Action
Conclusion
Insulin remains the most potent glucose-lowering agent available for the treatment of type 2 diabetes but has limitations, primarily of hypoglycemia and secondarily of weight gain. The addition of incretin-based therapies complements the glucose-lowering potential of basal insulin, without increasing the risk of hypoglycemia, potentially allowing for lower doses of insulin and without increasing weight gain (DPP-4 inhibitors) or possibly with weight loss (GLP-1 receptor agonists). Incretin-based therapies offer advantages over prandial insulin to address postprandial hyperglycemia.
Source: The Diabetes Educator - Category: Endocrinology Authors: Meece, J. D., Pearson, T. L., Siminerio, L. M. Tags: Features Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Incretin Therapy | Insulin | Study | Weight Loss